PITTSBURGH, Pa., September 21, 2011– Cohera Medical, a rapidly growing medical device company, announced today that the Company has received two Pittsburgh Technology Council Tech 50 Awards. Cohera Medical was recognized as the 2011 Life Sciences Company of the Year and its President and Chief Executive Officer, Patrick Daly, was named Pittsburgh CEO of the Year.
“We are honored to be recognized by the Pittsburgh Technology Council as a company that is developing unique and innovative technology that will help surgeons improve the overall care of their patients,” said Patrick Daly. “These awards are a reflection of the quality, commitment and passion of our entire team. We remain fully committed to supporting the technology business in Southwest Pennsylvania and making a positive impact on the lives of patients and surgeons worldwide.”
The Pittsburgh Technology Council’s Tech 50 Awards recognize southwestern Pennsylvania’s technology and thought-leading companies, which are innovation pioneers in technology-based industries that have become the backbone of Pittsburgh’s new economy. The council has over 270,000 members from more than 1,400 companies across the Southwestern Pennsylvania region.
The Life Sciences Company of the Year award is given to a company in the life sciences sector that improves our health and environment. The Pittsburgh CEO of the Year award is given to a CEO of a Tech 50 category company who makes a substantial contribution to his or her company performance and demonstrates outstanding leadership and high levels of peer esteem.
“Each year, the Pittsburgh Technology Council’s Tech 50 Awards honor those technology companies that demonstrate the strongest growth and advancement in products or sales success, financial strength, corporate citizenship, job growth and retention and innovative product or technology,” said Audrey Russo, President and CEO of the Pittsburgh Tech Council. “We congratulate Cohera Medical, Patrick Daly and its employees on this accomplishment.”
Cohera Medical recently received CE mark approval of its lead product in development, TissuGlu®Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union and the company plans to begin commercialization in Germany in the third quarter of 2011. Cohera Medical is also actively pursing U.S. FDA approval.
About Cohera Medical
Cohera Medical, Inc.® is a rapidly growing medical device company that is actively developing a line of surgical adhesives. Cohera Medical’s products are based on a unique chemical design that is resorbable, non-toxic, easy-to-use, and forms a strong bond between tissue layers. The Company’s lead product, TissuGlu® Surgical Adhesive, is designed to reduce fluid accumulation and the need for surgical drains in patients undergoing abdominoplasty (tummy tuck) and other plastic procedures that require the creation of large planar flaps of tissue. Cohera Medical is also developing surgical adhesives for use as bowel sealants, for hernia mesh fixation and for small bone fixation. Outside of the EU, TissuGlu Surgical Adhesive and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market.
For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.